GABA-glutamate Interactions and Psychosis

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Alliance for Research on Schizophrenia and Depression
• Treatments: Flumazenil

Criteria

Inclusion criteria:

• Ages of 21-45 years from all ethnic backgrounds.

• Male or female.

• Written informed consent.

Exclusion criteria:

• DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.

• A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, LFTs, TFTs, UA, Utox).

• History of abnormal EEG.

• History of severe allergies or multiple adverse drug reactions.

• Any medication that could interfere with either the safety of the study and/or the outcome measures.

• Any other conditions which in the opinion of the investigator would preclude participation in the study.

• History of major psychiatric disorder in first degree relatives.

• Current substance abuse/dependency determined by urine toxicology.

• Treatment with medications with CNS effects.

• Treatment with benzodiazepines within one week prior to testing.

• Current treatment with medications with psychotropic effects.

• Education < 10th grade.

• IQ < 70, MR.

• Non-English speaking.